Table 4 Non-manifesting carriers’ characteristics.
From: Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease
Control | LRRK2-NMC | GBA-NMC | Significance | |
|---|---|---|---|---|
# | 196 | 55 | 97 | |
Age (y) | 54.57 (11.32) | 52.89 (10.58) | 54.27 (9.59) | 0.517 |
Sex m/f | 89/107 | 28/27 | 36/61 | 0.377 |
Orthostatic Hypotension (%) | 7% | 10.09% | 10.30% | 0.516 |
MDS-UPDRS | 5.46 (4.35) | 5.69 (4.31) | 6.06 (6.79) | 0.449 |
MoCA | 26.46 (2.77) | 26.43 (2.74) | 25.86 (3.27) | 0.308 |
UPSIT | 30.39 (6.82) | 31.42 (4.93) | 29.45 (6.89) | 0.163 |
RBDQ | 1.75 (1.67) | 1.42 (1.57) | 1.98 (1.96) | 0.281 |
NMSQ | 3.39 (3.48) | 2.75 (2.78) | 3.35 (3.58) | 0.699 |
SCOPA-AUT | 8.42 (7.22) | 7.98 (5.96) | 8.47 (7.90) | 0.252 |
BDI | 4.16 (5.26) | 3.61 (4.70) | 4.22 (5.65) | 0.304 |
Probability of prodromal PD (%) | 10.95 (20.17) | 33.83 (31.54)@ | 16.09 (25.70) | 0.001 |
